Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):563-576. Published online January 13, 2025

DOI: https://doi.org/10.3350/cmh.2024.0899

View: 762 Download: 64

Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity

Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang

Clin Mol Hepatol. 2025;31(2):509-524. Published online January 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.0545

View: 1064 Download: 104

Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma

Weifeng Zeng, Furong Liu, Yachong Liu, Ze Zhang, Haofan Hu, Shangwu Ning, Hongwei Zhang, Xiaoping Chen, Zhibin Liao, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):489-508. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0934

View: 1840 Download: 274 Crossref: 5

Integrated molecular characterization of sarcomatoid hepatocellular carcinoma

Rong-Qi Sun, Yu-Hang Ye, Ye Xu, Bo Wang, Si-Yuan Pan, Ning Li, Long Chen, Jing-Yue Pan, Zhi-Qiang Hu, Jia Fan, Zheng-Jun Zhou, Jian Zhou, Cheng-Li Song, Shao-Lai Zhou

Clin Mol Hepatol. 2025;31(2):426-444. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0686

View: 1357 Download: 139

Reply to Correspondence

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):e121-e122. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0886

View: 929 Download: 35

Reply to correspondence on “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma”

Martina Mang Leng Lei, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(1):e119-e120. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0621

View: 885 Download: 34

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):e117-e118. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0994

View: 761 Download: 19

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Clin Mol Hepatol. 2025;31(1):e113-e116. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0867

View: 1030 Download: 31

Correspondence

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828

View: 965 Download: 48

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619

View: 971 Download: 32

Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Clin Mol Hepatol. 2025;31(1):e101-e102. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0946

View: 662 Download: 14

Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2025;31(1):e98-e100. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0916

View: 837 Download: 47

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829

View: 947 Download: 34 Crossref: 1

Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”

Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian

Clin Mol Hepatol. 2025;31(1):e58-e60. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0590

View: 950 Download: 56 Web of Science: 1 Crossref: 1

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Viewed By 8732	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7555	MAFLD: How is it different from NAFLD?
Viewed By 5454	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5057	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4580	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 292	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 203	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis